Alzamend Neuro Inc.’s positive preclinical data for AL-002 sent the company’s stock (NADAQ:ALZN) more than 70% higher before the market opened July 23. The Tampa, Fla.-based biopharma is researching a mutant-peptide sensitized cell for treating Alzheimer’s disease. The positive data came from a GLP toxicology study using a transgenic mouse model.
Adverum Biotechnologies Inc. CEO Laurent Fischer said the firm chose the more prudent route in scrapping development of gene therapy ADVM-022 (AAV.7m8-aflibercept) for diabetic macular edema (DME) as a result of dose-limiting toxicity in the phase II Infinity trial.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acadia, Antengene, Biosplice, GBT, Hemoshear, Heron, Ocuphire, Plus, Spark.
Foresight Diagnostics Inc. has developed a circulating tumor DNA (ctDNA) detection platform for detecting minimal residual disease (MRD) in B-cell lymphomas, a form of non-Hodgkin lymphoma and the most common lymphoma in the U.S., accounting for about 85% of all cases. Now, it has published data showing its phased variant enrichment detection sequencing (PhasED-Seq) nearly doubled the identification of patients with aggressive lymphoma who were not cured by standard therapy and need new treatment options.
Differences between Seres Therapeutics Inc.’s next-generation microbiome therapy and SER-287 were highlighted in the wake of the phase IIb failure with the latter in the study called Eco-Reset, which missed its primary endpoint of improving clinical remission rates in ulcerative colitis (UC) compared to placebo.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aprea, Biomarin, Dicerna, Eureka, Immunomolecular, Lumos, Scilex, Sorrento, Takeda.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Annovis, Anthos, Biomarin, Bonus, Ionctura, Lineage Cell, Mediwound, Merck, Ose, Rain, Sesen, SK Life, Wave.
Jiangsu Hengrui Medicine Co. Ltd. reported positive interim data from its phase III trial for SHR-3680, an androgen receptor antagonist, demonstrating that it reduced the risk of disease progression or death in metastatic hormone-sensitive prostate cancer patients with high-volume disease burden.
The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study showed that one of those vaccines, Sinovac Biotech Ltd.’s Coronavac, was less effective than Pfizer Inc. and Biontech SE’s Comirnaty in Chile.
Harbour Biomed Therapeutics Ltd. said its anti-FcRn monoclonal antibody, batoclimab, generated top-line phase II data in generalized myasthenia gravis, and the company expects to move into a phase III study by the end of this year, with final data reported in April 2022.
RSS
